At ANZUP 24 Cristiane Bergerot presented a new HRQOL measure for patients with localized and metastatic RCC – Florez Lab
Florez Lab shared on X:
“At ANZUP 24 Dr. Cristiane Bergerot presented a new HRQOL measure for patients with localized and metastatic RCC, developed with Dr. Tom Powles.
These advancements are paving the way for better patient care and outcomes!”
Source: Florez Lab/X
Cristiane D. Bergerot is the Director of the Department of Psycho-Oncology at CETTRO Cancer Research Hospital in Brasilia, Brazil. She has been working with cancer patients for almost 15 years as a clinician and as a researcher.
She has over 30 peer-reviewed publications in journals including first-author publications in Cancer, Journal of Immunotherapy for Cancer, British Journal of Urology International and Pscyhooncology.
Thomas Powles, specializing in urology cancer, holds the position of Professor at the University of London since 2012 and serves as the Director of Barts Cancer Centre, a CRUK Major Cancer Centre. With a role in biomarker development and drug strategies, he has secured multiple EMA and FDA approvals.
His achievements include advancing front-line immune/targeted therapy combinations in RCC and immune checkpoint inhibition in bladder cancer.
